UOSD Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
UOSD Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Cancer Lett. 2021 Mar 1;500:51-63. doi: 10.1016/j.canlet.2020.11.037. Epub 2020 Dec 6.
Lung cancer is the leading cause of cancer-related deaths, worldwide. Non-small cell lung cancer (NSCLC) is the most prevalent lung cancer subtype. YAP and TAZ have been implicated in lung cancer by acting as transcriptional co-activators of oncogenes or as transcriptional co-repressors of tumor suppressor genes. Previously we reported that YAP and TAZ regulate microRNAs expression in NSCLC. Among the set of regulated miRNAs, the oncogenic miR-25, 93, and 106b, clustering within the MCM7 gene were selected for further studies. We firstly identified Transforming Growth Factor-β (TGF-β) Receptor 2 (TGFBR2), a member of the TGF-β signaling, as a target of the miRNA cluster, which exhibited prognostic value because of its tumor suppressor activity. We found that YAP/TAZ-mediated repression of TGFBR2 occurs both: post-transcriptionally through the miR-106b-25 cluster and transcriptionally by engaging the EZH2 epigenetic repressor that we reported here as a novel target gene of YAP/TAZ. Furthermore, we document that YAP/TAZ and EZH2 cooperate in lung tumorigenesis by transcriptionally repressing a specific subset of tumor suppressor genes, including TGFBR2. Our findings point to YAP/TAZ and EZH2 as potential therapeutic targets for NSCLC treatment.
肺癌是全球癌症相关死亡的主要原因。非小细胞肺癌(NSCLC)是最常见的肺癌亚型。YAP 和 TAZ 通过作为癌基因的转录共激活因子或肿瘤抑制基因的转录共抑制因子参与肺癌的发生。先前我们报道 YAP 和 TAZ 调节 NSCLC 中的 microRNA 表达。在受调控的 microRNA 中,致癌的 miR-25、93 和 106b 聚类在 MCM7 基因内,被选为进一步研究的对象。我们首先鉴定出转化生长因子-β(TGF-β)受体 2(TGFBR2),TGF-β 信号通路的一个成员,作为 microRNA 簇的一个靶标,由于其肿瘤抑制活性,它具有预后价值。我们发现 YAP/TAZ 介导的 TGFBR2 抑制既发生在转录后通过 miR-106b-25 簇,也发生在通过结合我们在这里报道的作为 YAP/TAZ 的新型靶基因的 EZH2 表观遗传抑制剂。此外,我们记录到 YAP/TAZ 和 EZH2 通过转录抑制特定的肿瘤抑制基因子集(包括 TGFBR2)在肺癌发生中合作。我们的研究结果表明 YAP/TAZ 和 EZH2 可能是 NSCLC 治疗的潜在治疗靶点。